RxDoctor Payments Data

Alexander Richard, MD

Internal Medicine · New Orleans, LANPI 1417301441

Payments from drug & device makers

$2,868in general payments, 2019–2025

Across 102 payments — averaging $28.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$530
  • Amgen$507
  • Calliditas Therapeutics US Inc.$373
  • OPKO Pharmaceuticals, LLC$322
  • Otsuka America Pharmaceutical, Inc.$262
  • Vifor Pharma, Inc.$212
  • plus $663 from 13 others

What the payments were for

  • Food & beverage$2,83199%
  • Education$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,868 in reported general payments places this provider in the 75th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$88,237
Medicare patients
295
Services billed
813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin120$95,739
KerendiaFinerenone16$14,715
AuryxiaFerric Citrate13$12,704
FarxigaDapagliflozin Propanediol25$11,922
OzempicSemaglutide11$10,297
LokelmaSodium Zirconium Cyclosilicate11$7,370
Potassium Citrate ErPotassium Citrate27$1,897
Potassium Chloride55$1,200
Telmisartan72$1,121
Valsartan45$970
Olmesartan Medoxomil76$886
Losartan Potassium58$695
Midodrine Hcl14$617
Calcitriol36$554
Nifedipine ErNifedipine26$546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$530$14,71516 claims
Akebia Therapeutics IncAuryxia$65$12,70413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →